Pseudomyxoma peritonei originating from appendix tumors

ABSTRACT Background: Appendix tumors represent about 1% of all gastrointestinal neoplasia, in other words they are quite rare. However, there is a specific type of appendiceal neoplasms (mucinous adenocarcinoma) that spreads to the peritoneum and in almost 20% of the cases, resulting in a disease called pseudomyxoma peritonei. Although, it is a very rare condition, it is nonetheless a very severe one and therefore it is crucial to know how to correctly diagnose and treat it. Objective: This study provides updated data on how to diagnose, classify and treat pseudomyxoma peritonei that originates from appendix tumors. Methods: A bibliographic research was performed on PubMed database, including articles published since 2000, as well as, cross-referencing with the initial research. Discussion: In the past, patients diagnosed with pseudomyxoma peritonei would only undergo palliative measures, so their overall survival rate was greatly reduced. Over the years pseudomyxoma peritonei treatment has evolved and patients are now undergoing treatment which is a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. This new therapy has allowed an increase of survival chances of up to 5 years in those patients with values between 53% and 88%, depending on the type of tumor. Conclusion: Despite the great progress we have witnessed in recent years, which have led to a large increase in survival rates, more research needs to be done, on what to do when the disease is in an unresectable stage. Finding a less aggressive therapy than cytoreductive surgery + hyperthermic intraperitoneal chemotherapy will be an important step forward.

Saved in:
Bibliographic Details
Main Authors: Marques,Tatiana Maria Fernandes Moreira, Barbosa,Laura Elisabete Ribeiro
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Coloproctologia 2018
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632018000200164
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2237-93632018000200164
record_format ojs
spelling oai:scielo:S2237-936320180002001642018-06-14Pseudomyxoma peritonei originating from appendix tumorsMarques,Tatiana Maria Fernandes MoreiraBarbosa,Laura Elisabete Ribeiro Appendix tumors Pseudomyxoma peritonei Cancer diagnosis Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy ABSTRACT Background: Appendix tumors represent about 1% of all gastrointestinal neoplasia, in other words they are quite rare. However, there is a specific type of appendiceal neoplasms (mucinous adenocarcinoma) that spreads to the peritoneum and in almost 20% of the cases, resulting in a disease called pseudomyxoma peritonei. Although, it is a very rare condition, it is nonetheless a very severe one and therefore it is crucial to know how to correctly diagnose and treat it. Objective: This study provides updated data on how to diagnose, classify and treat pseudomyxoma peritonei that originates from appendix tumors. Methods: A bibliographic research was performed on PubMed database, including articles published since 2000, as well as, cross-referencing with the initial research. Discussion: In the past, patients diagnosed with pseudomyxoma peritonei would only undergo palliative measures, so their overall survival rate was greatly reduced. Over the years pseudomyxoma peritonei treatment has evolved and patients are now undergoing treatment which is a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. This new therapy has allowed an increase of survival chances of up to 5 years in those patients with values between 53% and 88%, depending on the type of tumor. Conclusion: Despite the great progress we have witnessed in recent years, which have led to a large increase in survival rates, more research needs to be done, on what to do when the disease is in an unresectable stage. Finding a less aggressive therapy than cytoreductive surgery + hyperthermic intraperitoneal chemotherapy will be an important step forward.info:eu-repo/semantics/openAccessSociedade Brasileira de ColoproctologiaJournal of Coloproctology (Rio de Janeiro) v.38 n.2 20182018-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632018000200164en10.1016/j.jcol.2017.11.007
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Marques,Tatiana Maria Fernandes Moreira
Barbosa,Laura Elisabete Ribeiro
spellingShingle Marques,Tatiana Maria Fernandes Moreira
Barbosa,Laura Elisabete Ribeiro
Pseudomyxoma peritonei originating from appendix tumors
author_facet Marques,Tatiana Maria Fernandes Moreira
Barbosa,Laura Elisabete Ribeiro
author_sort Marques,Tatiana Maria Fernandes Moreira
title Pseudomyxoma peritonei originating from appendix tumors
title_short Pseudomyxoma peritonei originating from appendix tumors
title_full Pseudomyxoma peritonei originating from appendix tumors
title_fullStr Pseudomyxoma peritonei originating from appendix tumors
title_full_unstemmed Pseudomyxoma peritonei originating from appendix tumors
title_sort pseudomyxoma peritonei originating from appendix tumors
description ABSTRACT Background: Appendix tumors represent about 1% of all gastrointestinal neoplasia, in other words they are quite rare. However, there is a specific type of appendiceal neoplasms (mucinous adenocarcinoma) that spreads to the peritoneum and in almost 20% of the cases, resulting in a disease called pseudomyxoma peritonei. Although, it is a very rare condition, it is nonetheless a very severe one and therefore it is crucial to know how to correctly diagnose and treat it. Objective: This study provides updated data on how to diagnose, classify and treat pseudomyxoma peritonei that originates from appendix tumors. Methods: A bibliographic research was performed on PubMed database, including articles published since 2000, as well as, cross-referencing with the initial research. Discussion: In the past, patients diagnosed with pseudomyxoma peritonei would only undergo palliative measures, so their overall survival rate was greatly reduced. Over the years pseudomyxoma peritonei treatment has evolved and patients are now undergoing treatment which is a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. This new therapy has allowed an increase of survival chances of up to 5 years in those patients with values between 53% and 88%, depending on the type of tumor. Conclusion: Despite the great progress we have witnessed in recent years, which have led to a large increase in survival rates, more research needs to be done, on what to do when the disease is in an unresectable stage. Finding a less aggressive therapy than cytoreductive surgery + hyperthermic intraperitoneal chemotherapy will be an important step forward.
publisher Sociedade Brasileira de Coloproctologia
publishDate 2018
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632018000200164
work_keys_str_mv AT marquestatianamariafernandesmoreira pseudomyxomaperitoneioriginatingfromappendixtumors
AT barbosalauraelisabeteribeiro pseudomyxomaperitoneioriginatingfromappendixtumors
_version_ 1756440316019212288